Theriva Sells SYN-004 and Related Portfolio to Biossil Labs
Theriva received $350,000 upfront at closing and is eligible for up to $91 million in regulatory and sales milestones, plus low single-digit royalties on net product sales. Biossil will assume future development and commercialization responsibilities and costs.
Story updates
01:02:40 PM UTC
SquawkNews
Theriva sold its antibiotic-degrading enzyme portfolio to Biossil for $350.0K upfront, with up to $3M in regulatory milestones, up to $88M in sales milestones and low single-digit royalties capped at $250M. No prior-period comparison was provided.Material DetailsContext by AI AnalystThis transactio…
Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along with low single-digit royalties on net product sales —— Biossil to assume all responsibility and costs for future development and commercialization of the antibio…